If you have been reading about thymosin alpha-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
In Iceland, flunitrazepam is a controlled substance available from Mylan. It is prescribed for severe insomnia and is sometimes used before surgery to induce a calm, relaxed state of mind for the patient. In Sweden, flunitrazepam is a List II drug (substances with medicinal uses) under the Narcotics Control Act (1968). It was previously available from Mylan, but has been removed from the market in January 2020. In the United Kingdom, flunitrazepam is not licensed for medical use and is a controlled drug under Schedule 3 and Class C. In the United States, the drug has not been approved by the Food and Drug Administration and is considered to be an illegal drug; as of 2016 it is Schedule IV. 21 U.S.C. § 841 and 21 U.S.C. § 952 provide for punishment for the importation and distribution of up to 20 years in prison and a fine; possession is punishable by three years and a fine. Travelers travelling into the United States are limited to a 30-day supply. The drug must be declared to US Customs upon arrival. If a valid prescription cannot be produced, the drug may be subject to Customs search and seizure, and the traveler may face criminal charges or deportation.
== Population pharmacokinetics == Population pharmacokinetics (popPK) is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest. Certain patient demographic, pathophysiological, and therapeutical features, such as body weight, excretory and metabolic functions, and the presence of other therapies, can regularly alter dose-concentration relationships and can explain variability in exposures. For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients with kidney failure than they are in patients with normal kidney function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors and explain sources of variability that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically relevant and significant shifts in exposures that impact the therapeutic index, dosage can be appropriately modified. Additionally, an advantage of population pharmacokinetic modelling is its ability to analyze sparse data sets (sometimes only one concentration measurement per patient is available).
=== TCI-Concor Multimodal Solutions Private Limited === Transport Corporation of India Limited and Container Corporation of India joint venture, the company provides multimodal rail road logistics services by combining TCI’s road transport network with CONCOR’s rail infrastructure.
Sources: en.wikipedia.org
The open circuit demand system exhausts gas to the environment at ambient pressure (or a very small difference from ambient pressure required to open the exhaust valve). As a result, all exhaled gas is lost to the surroundings. For most surface orientated commercial diving where air is the breathing gas in use, this is no problem, as air is cheap and freely available. Even with nitrox it is generally more cost effective to use open circuit, as oxygen is an easily available and relatively inexpensive gas, and blending nitrox is technologically simple, both to mix and to analyse.
== Research == Brodbelt's research centers on the development of mass spectrometry-based methods to characterize organic molecules. Brodbelt's early research established methods to use chemical ionization in ion trap mass spectrometers and applied this method to the analysis of petroleum samples. She subsequently worked on gas-phase ion chemistry and photodissociation as methods to break apart organic compounds before they are analyzed by a mass spectrometer. Her work has led to the analysis of compounds including recreational drugs, sunscreen, and pesticides. Her work also includes investigations into proteins and other organic compounds produced by bacteria, such as lipopolysaccharides. In her research, she aimed to develop creative techniques for stimulating ions to produce enlightening fragmentation patterns.
Episode Two was released for Windows, Xbox 360 and PlayStation 3 on October 10, 2007, as part of the compilation The Orange Box. It was distributed digitally on Steam and at retail by Electronic Arts. Episode Two focuses on expansive environments, travel and less linear play. As Freeman, the player travels with Alyx into the surrounding countryside, pursued by Combine forces. Episode Two's new technologies and gameplay features were praised by reviewers; however, though it was significantly longer than Episode 1, the length was again a point of criticism.
Sources: en.wikipedia.org
=== Anti-aging and rejuvenation treatment === Solar UV radiation accelerates the skin ageing rate and contributes to abnormal cutaneous status by increasing matrix-metalloproteinase (MMP) expression in photo-damaged skin. MMPs consist of various proteinases that degrade collagen fibrils and other components of the cutaneous extracellular matrix. The commonly used therapies for skin ageing involve the use of retinoic acid, laser resurfacing, peels (trichloroacetic acid and CO2), injectable skin rejuvenation, and dermal fillers. In comparison, LEDT is a more non-ablative cutaneous rejuvenation approach with less safety concern and higher effectiveness. LECT with yellow LED (at a wavelength of 590 nm) contributes to the skin rejuvenation effects on nearly a thousand clinical samples. Researchers conclude that the use of red-light LEDT is an efficient collagen enhancement strategy. LEDT's combination therapy of different light wavelengths also shows greater efficacy. For instance, blue-light LEDT coupled with photosensitizers reveals better elasticity, less pigmentation, and more complexion of the skin.
=== Vitamin content of frozen fruits and vegetables === Vitamin C: Usually lost in a higher concentration than any other vitamin. A study was performed on peas to determine the cause of vitamin C loss. A vitamin loss of 10% occurred during the blanching phase with the rest of the loss occurring during the cooling and washing stages. The vitamin loss was not actually accredited to the freezing process. Another experiment was performed involving peas and lima beans. Frozen and canned vegetables were both used in the experiment. The frozen vegetables were stored at −23 °C (−10 °F) and the canned vegetables were stored at room temperature 24 °C (75 °F). After 0, 3, 6, and 12 months of storage, the vegetables were analyzed with and without cooking. O'Hara, the scientist performing the experiment said, "From the view point of the vitamin content of the two vegetables when they were ready for the plate of the consumer, there did not appear to be any marked advantages attributable to method of preservation, frozen storage, processed in a tin, or processed in glass." Vitamin B1 (thiamin): A vitamin loss of 25% is normal. Thiamin is easily soluble in water and is destroyed by heat. Vitamin B2 (riboflavin): Not much research has been done to determine how freezing affects riboflavin levels. Studies that have been performed are inconclusive. One study found an 18% vitamin loss in green vegetables, while another found a 4% loss. It is commonly accepted that the loss of riboflavin has to do with the preparation for freezing rather than the freezing process itself.
=== Global market === The global jerky snacks market size was valued at $5.66 billion in 2024. It is expected to reach $8.81 billion by 2033, exhibiting a compound annual growth rate of 4.79% from 2025–2033. North America dominates the market, holding a market share of over 50.0% in 2024.
Several trials have attempted dietary interventions with the hope of reducing the autoimmunity that leads to type 1 diabetes. Trials that withheld cow's milk or gave infants formula free of bovine insulin decreased the development of β-cell-targeted antibodies, but did not prevent the development of type 1 diabetes. Similarly, trials that gave high-risk individuals injected insulin, oral insulin, or nicotinamide did not prevent diabetes development. Other strategies under investigation for the prevention of type 1 diabetes include gene therapy, stem cell therapy, and modulation of the gut microbiome. Gene therapy approaches are still in early stages. They aim to alter genetic factors that contribute to beta-cell destruction by editing immune responses. Stem cell therapies are also being researched, with the hope that they can either regenerate insulin-producing beta cells or protect them from immune attack. Trials using stem cells to restore beta cell function or regulate immune responses are ongoing. Modifying the gut microbiota through the use of probiotics, prebiotics, or specific diets has also gained attention. Some evidence suggests that the gut microbiome plays a role in immune regulation, and researchers are investigating whether altering the microbiome could reduce the risk of autoimmunity and, subsequently, type 1 diabetes. Tolerogenic therapies, which seek to induce immune tolerance to beta-cell antigens, are another area of interest.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.